Comparative Pharmacology
Head-to-head clinical analysis: ADDERALL XR 30 versus DEXEDRINE SPANSULE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADDERALL XR 30 versus DEXEDRINE SPANSULE.
ADDERALL XR 30 vs DEXEDRINE SPANSULE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adderall XR is a central nervous system (CNS) stimulant. It contains a mixture of amphetamine salts (dextroamphetamine and levoamphetamine). Amphetamines are non-catecholamine sympathomimetic amines that promote release of catecholamines (primarily dopamine and norepinephrine) from presynaptic nerve terminals and inhibit their reuptake, leading to increased synaptic concentrations. The exact mechanism of action in attention deficit hyperactivity disorder (ADHD) is not fully understood but is thought to involve activation of dopaminergic and noradrenergic pathways in the prefrontal cortex.
Dextroamphetamine is a central nervous system (CNS) stimulant that increases synaptic concentrations of norepinephrine and dopamine by blocking their reuptake and promoting release from presynaptic terminals.
20-60 mg orally once daily in the morning; start at 20 mg once daily, titrate by 10 mg weekly based on tolerability and response.
5-60 mg orally once daily in the morning, using extended-release capsules.
None Documented
None Documented
The terminal elimination half-life is 10–13 hours for dextroamphetamine (the more active enantiomer) in adults; for the racemic mixture (dextroamphetamine/amphetamine), the half-life is shorter (6–8 hours) due to differential metabolism. Clinical context: Steady-state achieved within 2–3 days; once-daily dosing is sufficient.
Terminal elimination half-life is 6-8 hours in adults, 10-13 hours in children, and prolonged in alkaline urine (up to 16-20 hours) due to enhanced tubular reabsorption. In hepatic impairment, half-life may extend to 12-15 hours. Steady-state is reached within 2-3 days.
Renal: approximately 90% (30–40% unchanged, remainder as metabolites including dehydroamphetamine and hydroxylated metabolites). Fecal: <4%. Biliary: minimal.
Renal excretion of unchanged drug (approximately 30-40% unchanged) and hepatic metabolism to inactive metabolites (primarily hippuric acid, benzoic acid, and hydroxylated derivatives). About 90% of a dose is excreted in urine within 48 hours, with 10-15% as unchanged dextroamphetamine; minor biliary/fecal elimination (<5% total).
Category C
Category C
CNS Stimulant
CNS Stimulant